期刊文献+

益气温经方防治绝经后骨质疏松性髋部骨折的骨密度及SF-36疗效评价 被引量:24

Clinical Study of Yiqi Wenjing Recipe in Preventing and Treating Primary Type I Osteoporotic Hip Fractures with BMD and SF-36 Quality of Life Score
原文传递
导出
摘要 目的通过骨密度(bone mineral density,BMD)比较、SF-36生存质量评分指标的变化来观察益气温经方(即强骨饮颗粒)治疗绝经后骨质疏松性髋部骨折的临床疗效。方法以2013年6月—2014年8月在浙江中医药大学附属第二医院骨科的绝经后骨质疏松性髋部骨折患者为研究对象,将符合入选标准的120例患者随机分为益气温经方组、基础用药组和仙灵骨葆组,每组40例。基础用药组每日服用钙尔奇D3片和阿法骨化醇胶囊;仙灵骨葆组在基础用药组的基础上,加仙灵骨葆胶囊;益气温经方组在基础用药组的基础上,加益气温经方。经6个月治疗后,观察各组BMD和SF-36生存质量评分。结果治疗6个月后,益气温经方组和仙灵骨葆组经治疗后BMD均有提高(P<0.05),优于基础用药组(P<0.05);益气温经方组BMD的平均增加量(2.21%)高于仙灵骨葆组(1.95%),差异无统计学意义;与基础用药组相比,2组平均变化率比较有明显差异(P<0.05)。各组治疗后各维度生存质量评分均有上升,各维度组内治疗前后比较,差异有统计学意义(P<0.05);益气温经方组在生理功能、生理职能、活力、社会功能方面优于基础用药组(P<0.05);在躯体疼痛、总体健康、情感职能、精神健康方面,与各组间差异无统计学意义。结论益气温经方防治绝经后骨质疏松性髋部骨折可有效提高患者的生存质量,提升其腰椎的BMD。 OBJECTIVE To observe the clinical efficacy of Yiqi Wenjing recipe in treating postmenopausal osteoporotic hip fractures by changing bone mineral density(BMD), SF-36 quality of life score. METHODS The postmenopausal osteoporotic hip fracture patients were objected for study, who visited the Second Affiliated Hospital of Zhejiang Chinese Medical University from June 2013 to August 2014. The 120 patients met the inclusion criteria were randomly divided into three groups, the Yiqi Wenjing recipe group, basic medication group and Xianlinggubao group, 40 cases in each group. Basic medication group given Calcium Carbonate Chewable D3 1.0 g and alfacalcidol capsules everyday; Xianlinggubao group was based on basic medication group to plus Xianlinggubao capsule; Yiqi Wenjing recipe group was based on basic medication group to plus Yiqi Wenjing recipe. All of the groups gave 6 months treatment. Measured bone mineral density(BMD), SF-36 quality of life score. RESULTS After 6 months of treatment, the BMD of Yiqi Wenjing recipe group and Xianlinggubao group were both increased slightly(P〈0.05), which were both had advantage over basic medication group(P〈0.05). However, there were significant differences in the two groups compared the average rate of change(P〈0.05); the average increase in BMD with Yiqi Wenjing recipe group(2.21%) were higher than the Xianlinggubao group(1.95%). In all groups after treatment, all dimensions of quality of life score increased significantly(P〈0.05). Four dimensions including the physiological function, vitality, physiological function, social function in Yiqi Wenjing recipe group were improved obviously than basic medication group(P〈0.05). While four dimensions including somatic pain, mental health, emotional functioning, general health had no significant difference compared with other groups. CONCLUSION Yiqi Wenjing recipe in preventing and treating of postmenopausal osteoporotic hip fractures can effectively improve the quality of life, promote the BMD.
出处 《中国现代应用药学》 CAS CSCD 2015年第5期592-595,共4页 Chinese Journal of Modern Applied Pharmacy
基金 国家中医药行业科研专项(201307010) 2012年浙江省中医药重点项目(2012ZZ007)
关键词 益气温经方 绝经后骨质疏松症 髋部骨折 骨密度 Yiqi Wenjing recipe postmenopausal osteoporosis hip fracture bone mineral density(BMD)
  • 相关文献

参考文献6

二级参考文献32

  • 1史晓林.自拟强骨饮治疗骨质疏松症的32例临床报告[J].中国中医骨伤科杂志,2006,14(2):57-58. 被引量:24
  • 2李春雯,毛应德龙,史晓林.强骨饮对去势大鼠股骨颈骨形态计量学的影响[J].中国骨质疏松杂志,2007,13(6):433-435. 被引量:9
  • 3ZOARSKI G H, SNOW P, OLAN W J, et al. Percutaneous vertebroplasty for osteoporotic compression fractures: quantitativeprospective evaluation of long-term outcomes [J]. Vasc Interv Radiol, 2002, 13(2): 139-148.
  • 4MURPHY K J, DERAMOND H. Percutaneous vertebroplasty in benign and malignant disease [J]. Neuroimaging Clin N Am, 2000, 10(3): 535-545.
  • 5YUAN Y X, LI Q, MEI Z, et al. Zoledronic sodium effect of the treatment of elderly osteoporosis elderly zosteoporosis with 98 cases [J].胃肠病学,2012,32(11):2395—2396.
  • 6Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multieth nic cohort of women[J]. J Clin Endocrinol Metab, 2008, 93 (4) :861-868.
  • 7Rossouw JE, Prentice RI., Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause[J]. Jama,2009, 297(34) : 1465-1475.
  • 8Murphy PA, Barua K, Hauck CC. Solvent extraction selection in the determination of isoflavones in soy foods [J]. J Chromatogr B Anal Technol Biomed Life Sci,2009, 777(12) : 129-138.
  • 9Erp-Baart MA, Brants HA, Kiely M, et al. Isoflavone intake in four different European countries: the VENUS approach [J]. Br J Nutr,2008, 89(Suppl1):S25-S30.
  • 10Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes[J]. Nutr Cancer, 21107,55 (19): 111-129.

共引文献1882

同被引文献326

引证文献24

二级引证文献202

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部